Metabolic Surgery for Atrial Fibrillation Elimination

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 100 participants.

Also called NCT07027969

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07027969
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07027969. Randomized; no masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2029-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Metabolic Surgery for Atrial Fibrillation Elimination
Acronym
METSAFE
Condition
Obesity and Obesity-related Medical Conditions
Intervention (Procedure)
Roux-en-Y Gastric Bypass or Sleeve Gastrectomy
Intervention (Drug)
Anti-Obesity Medication (AOM) treatment
Lead sponsor
Ali Aminian (class: other)
Collaborator
Ethicon, Inc. (class: industry)
Collaborator
iRhythm Technologies, Inc. (class: industry)

Record details

Record id
cardio:ct-nct07027969
Content hash
166635191a27e9e1422b893d156b14b8c5425127b80adb9f75a8a3bb7eb22edc